StreetAlpha.app
Home › Stocks › ANEB

Anebulo Pharmaceuticals, Inc. (ANEB)

$0.28
▲ +7.69%
LAST CLOSE · NOV 17

Anebulo develops selonabant, an experimental drug for treating cannabis toxicity, mainly aimed at children and emergency departments. It last closed at $0.28 on Nov 17, up 7.69% on the day. ANEB reports earnings on Wed, Nov 18, 2026.

AI Auto Pilots
Is ANEB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$8.0M
EPS (diluted)
−$0.18
Valuation
Market cap
$11.4M
40.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$9.0M
At Dec 31
Shareholder equity
$7.9M
Shares outstanding
40.8M
At Feb 6
Fiscal year endsJune
ExchangeOTC
Financials history
FY2021: −$30.3M−$30.3MFY2021FY2022: −$6.8M−$6.8MFY2022FY2023: −$11.7M−$11.7MFY2023FY2024: −$8.2M−$8.2MFY2024FY2025: −$8.5M−$8.5MFY2025

From ANEB's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Feb 12). Last 12 months adds up the four latest quarters.

Next report
Nov 18
2026 · Time not announced
Consensus EPS forecast
-$0.11
 
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
—
No ratings in 90 days
Loading…

Technical Analysis

ANEB · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock sits between its 20 and 50 day averages. It is 53% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the 20 day average at $0.27, and the nearest resistance the swing high (Nov 9) at $0.29.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 13.7%/day
Key levels
$2.4952 week high+789.3%
$0.43200 day average+53.6%
$0.31100 day average+10.7%
$0.2950 day average+3.6%
$0.29Swing high (Nov 9)+3.6%
$0.28Pivot R1+0.0%
$0.28Pivot+0.0%
$0.28Pivot S1+0.0%
$0.28Last close
$0.2720 day average−3.6%
$0.26Swing low (Nov 11)−7.1%
Indicators
RSI (14)51.55Middle of its rangeNeutral
MACD0.00Below its signal lineBearish
Stochastic94.2Near the top of its rangeOverbought
ADX (14)72.8Strong downtrend
Williams %R-3.5Oversold below −80, overbought above −20Overbought
CCI (20)51.1Oversold below −100, overbought above 100Neutral
Rate of change+7.7%Change over 10 sessionsBullish
ATR (14)$0.04Typical daily range, 13.7% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANEB

What happened before

See how ANEB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Earnings in less than a daySignals right before a report are less reliable. The report can override them.
November seasonalityHow ANEB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ANEB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ANEB in the last 90 days.

Loading…

See today’s whale options flow across the market →

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANEB is in one of them and how their past ANEB trades turned out.

ANEB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANEB in an article yet. Here's the latest on the wider market.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals is a drug developer based in Lakeway, Texas, working on treatments for cannabis toxicity. Its lead candidate, selonabant, is designed to reverse the effects of cannabis intoxication and shorten recovery time. The company is focused on an intravenous version for children who have been accidentally poisoned by cannabis, with emergency departments as the intended users. Selonabant is still in clinical development and has not been approved for sale.

Headquarters
Lakeway, TX